DexCom, Inc. (DXCM), a medical device company, is set to announce its Q3 earnings for 2025 with a market cap of $25.5 billion. Analysts predict a profit of $0.57 per share, a 26.7% increase from the previous year. For fiscal 2025, a profit of $2.04 per share is expected, with further growth in fiscal 2026.

Despite a 4.7% decline in shares over the past year, DexCom outperformed the Health Care Select Sector SPDR Fund but lagged behind the S&P 500 Index. Following better-than-expected Q2 results, the company’s stock received a “Strong Buy” rating from Wall Street analysts, with a mean price target of $100.24, indicating a 52.5% potential upside.

Read more at Yahoo Finance: DexCom Earnings Preview: What to Expect